课题基金 / 基金详情

An Empirical Study on the Intellectual Property Strategy and Real Options Analysis of the Biotech Start-ups

An Empirical Study on the Intellectual Property Strategy and Real Options Analysis of the Biotech Start-ups
生物科技初创企业知识产权战略与实物期权分析实证研究
批准号:
17402027
负责人:
FUJIWARA Takao
金额:
$5.91万
依托单位国家:
日本
项目类别:
Grant-in-Aid for Scientific Research (B)
财政年份:
2005
资助国家:
日本
项目状态:
已结题
起止时间:
2005 至 2007

项目摘要

项目成果

FUJIWARA Takao的其他基金

相似基金

相关文献

中文摘要
翻译
本项目主要研究真实的期权分析(罗阿)的潜力和局限性,因为罗阿常被美国和英国的生物技术初创企业或大型制药公司作为决策制定方法,使基于基础研究的药物开发成为可能。罗阿研究的另一个目的是为了通过量化的方法来恢复日本的管理风格,以赶上美国或英国等先进国家的生物技术初创企业的创建活动。根据这个项目,他们是一些有前途的生物技术初创企业,这些企业正在经营或在日本的生物技术聚集地,如北海道,关东,关西,九州,其次,本研究表明,真实的可选择性设计可以从消极的设计转变为消极的设计, ...更多信息 e NPW(Net Present Value)在一定范围内转化为正ENPV(Expanded NPV),而药物发现类生物技术初创企业由于长期处于负现金流期,往往面临死亡谷。此外,通过使用蒙特卡罗模拟,随机罗阿可以显示一个定量模型,不仅提高了预期收益值从负值到正值,但同时也降低了风险,基于多个场景从模拟,而不是一个点估计的一个场景从一个二项式格模型。摘要为使生物技术创业企业在战略合作伙伴关系中做出理性决策,以克服“死亡谷”,尝试将真实的期权与博弈论相结合,采用期权博弈的探索性方法进行建模。在定量竞争和定价竞争的条件不同的情况下,研究表明,即使是非合作博弈也可以指导合作伙伴关系或开放式创新的最优策略,本研究的意义在于:提出了一种基于知识产权的最优策略设计,并建立了与大型制药公司战略合作的最优策略选择模型,由于创业公司比大公司更适合于创新性和高风险的药物开发项目,因此,本研究的重要意义在于建立和检验生命科学基础研究成果商业化长期投资决策的量化管理模型,因为在未来老龄化的背景下,生物技术产业正变得重要,并且是继汽车产业之后的下一代产业。少
英文摘要
In this project, the potential and limit of Real Options Analysis(ROA)are mainly studied, because ROA is often used by the US and UK pioneering biotech start-ups or large pharmaceutical companies as a decision malting method to make possible irmovative the drug development based on basic research for clinical serious diseases. Another objective of this study on ROA is came from one intention to make recovery of Japanese Management Style by a quantitative approach in order to catch-up on founding activities of Japanese biotech start-up with advanced countries as the US or UK.According to this project, fast of all, them are some promising biotech start-ups that am operating or founding in such Japanese biotech dusters as the Hokkaido, Kanto, Kansai, Kyusyu, and Chubu areas, mainly because of establishing the technological transfer process from the basic research of life science to the bus ness or market Secondly, this study showed that the real optional design could change from a negativ … More e NPW (Net Present Value) into a positive ENPV (Expanded NPV) within a certain extent, while drug discovery biotech start-ups tend to face the death-valley, as long term of negative cash flow period. Additionally by using Monte Carlo simulation, stochastic ROA could show a quantitative model on not only the improvement of the expected return value from a negative to a positive value but also simultaneously the reduction of risk, based on multiple scenarios from simulation instead of a point estimation of one scenario from a binomial lattice model Thirdly, for a rational decision making at strategic partnerships as a method to overcome the death-valley by biotech start-ups, a modeling in an exploratory approach of option-game was tried for the integration between real options and game theory. While the conditions between the quantitative and the pricing competition modes are different, the study made dear a possibility that even non-cooperative game could guide to the optimal strategy for partnerships or open innovation.Some of significances of this study are a teal optional design based on intellectual property and a modeling on the optimal strategy selection from the option-game at strategic partnerships with large pharmaceutical companies, for drug discovery biotech start-ups to overcome the death-valley, because start-ups are more suitable than large companies for the innovative and risky drug development projects.The importance of the study is the building and test of the quantitative management model on long term investment decision for commercialization of basic research results in life science, since biotech industry is becoming important in the context of the future aging and as a next generation of industry after the automotive industry. Less
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
The Survival Approach of during death-valley of academic biotech start-ups
学术生物科技初创企业死亡谷的生存之道
DOI: --
发表时间: 2006
期刊: Proceedings of 17^<th>ISPIM Annual Conference, Athens, Greece 11-14 June (in CD-ROM)
影响因子: --
作者: [Takao Fujiwara, Takao Fujiwara, Takao Fujiwara, 藤原 孝男, Takao Fujiwara, Takao Fujiwara, Takao Fujiwara]
通讯作者: Takao Fujiwara
Japan's Health-Care Quality and Application of Real Options to the Flexible Decision-Making Strategy for Biotech Start-up
日本的医疗保健质量以及实物期权在生物技术初创企业灵活决策策略中的应用
DOI: --
发表时间: 2008
期刊: the Global Journal of Flexible Systems Management Volume9 No1(in printing)
影响因子: --
作者: [Takao Fujiwara]
通讯作者: Takao Fujiwara
Japan's Healthcare and ApplingRealOptionstoBiotechStart-ups
日本的医疗保健和生物技术初创企业的真实期权应用
DOI: --
发表时间: 2007
期刊: Proceedings of 2007 AIB SOUTHEAST ASIAREGIONAL CONFERENCE
影响因子: --
作者: [大隅昇, 前田忠彦, Takao Fujiwara, 前田忠彦, Takao Fujiwara, Tadahiko Maeda, 藤原孝男, Takao Fujiwara, Takao Fujiwara, Takao Fujiwara, 藤原 孝男, Takao Fujiwara, Takao Fujiwara]
通讯作者: Takao Fujiwara
DOI: --
发表时间: 2006
期刊: 研究・技術計画学会第21回年次学術大会講演要旨集(東北大学) 10月21-22日
影响因子: --
作者: [Takao Fujiwara, Takao Fujiwara, Takao Fujiwara, 藤原 孝男]
通讯作者: 藤原 孝男
共 16 条
    Real Options Function for Survival of Biotech Start-ups in Commercializing Life Science Findings
    • 批准号:
      21330090
    • 项目类别:
      Grant-in-Aid for Scientific Research (B)
    • 资助金额:
      $12.06万
    • 财政年份:
      2009
    • 负责人:
      FUJIWARA Takao
    • 依托单位:
    An investigative Study on Technology Transfer and Venture Capital in Commercialization of Life Science
    • 批准号:
      13572025
    • 项目类别:
      Grant-in-Aid for Scientific Research (B)
    • 资助金额:
      $5.44万
    • 财政年份:
      2001
    • 负责人:
      FUJIWARA Takao
    • 依托单位:
    海外基金